Cargando…

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting about 0. 5–1% of the adult population and manifesting as persistent synovitis, systemic inflammation and production of autoantibodies. Patients affected by RA not only experience chronic disease progression, but are also burdened...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giachi, Andrea, Cugno, Massimo, Gualtierotti, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637771/ https://www.ncbi.nlm.nih.gov/pubmed/36352850 http://dx.doi.org/10.3389/fcvm.2022.1012661

Ejemplares similares

Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis
por: Baoqi, Yang, et al.
Publicado: (2022)

Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases
por: Gualtierotti, Roberta, et al.
Publicado: (2018)

Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis
por: Mangoni, Arduino A., et al.
Publicado: (2021)

Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?
por: Atzeni, Fabiola, et al.
Publicado: (2021)

Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis
por: Gualtierotti, Roberta, et al.
Publicado: (2017)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Editorial: The molecular mechanisms and therapeutic targets of atherosclerosis
por: Gualtierotti, Roberta, et al.
Publicado: (2023)

Improvements in High-Density Lipoprotein Quantity and Quality Contribute to the Cardiovascular Benefits by Anti-tumor Necrosis Factor Therapies in Rheumatoid Arthritis: A Systemic Review and Meta-Analysis
por: Luo, Yonghong, et al.
Publicado: (2021)

A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs
por: Panchal, Viraj, et al.
Publicado: (2023)

Lung Ultrasound Findings and Endothelial Perturbation in a COVID-19 Low-Intensity Care Unit
por: Gualtierotti, Roberta, et al.
Publicado: (2022)

Regulatory T Cell Suppressive Activity Predicts Disease Relapse During Disease-Modifying Anti-rheumatic Drug Dose Reduction in Rheumatoid Arthritis: A Prospective Cohort Study
por: Kanjana, Korawit, et al.
Publicado: (2020)

Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis
por: Si, Lulu, et al.
Publicado: (2022)

Vascular Age, Metabolic Panel, Cardiovascular Risk and Inflammaging in Patients With Rheumatoid Arthritis Compared With Patients With Osteoarthritis
por: Rodríguez-Vargas, Gabriel-Santiago, et al.
Publicado: (2022)

Relationship between rheumatoid arthritis and cardiovascular comorbidity, causation or co-occurrence: A Mendelian randomization study
por: Wang, Min, et al.
Publicado: (2023)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Exploring the treatment burden of disease-modifying anti-rheumatic drug monitoring in people with rheumatoid arthritis
por: Ryan, Sarah, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis
por: Giollo, Alessandro, et al.
Publicado: (2021)

Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial
por: Svensson, Annemarie Lyng, et al.
Publicado: (2016)

Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?
por: Bartoloni, Elena, et al.
Publicado: (2018)

Nailfold Videocapillaroscopic Alterations as Markers of Microangiopathy in COVID-19 Patients
por: Gualtierotti, Roberta, et al.
Publicado: (2023)

Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
por: Pascual-Ramos, Virginia, et al.
Publicado: (2013)

Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
por: Heidari, Behzad, et al.
Publicado: (2012)

Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy
por: Khalid, Sabeen, et al.
Publicado: (2019)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs
por: Arias de la Rosa, Iván, et al.
Publicado: (2021)

Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
por: Hanaoka, Hironari, et al.
Publicado: (2022)

Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
por: Fan, Junyu, et al.
Publicado: (2023)

Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis
por: Kobayashi, Masatake, et al.
Publicado: (2021)

Periodontal Condition in Patients with Rheumatoid Arthritis: Effect of Anti-rheumatic Drugs
por: Kordtabar, Samira, et al.
Publicado: (2019)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
por: Tawaratsumida, Hiroki, et al.
Publicado: (2017)

Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
por: Kurata, Izumi, et al.
Publicado: (2019)

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
por: Birkner, Benjamin, et al.
Publicado: (2020)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Population-based assessment of cardiovascular complications of rheumatic heart disease in Fiji: a record-linkage analysis
por: Parks, Tom, et al.
Publicado: (2023)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort
por: Zou, Yao-Wei, et al.
Publicado: (2022)

The rise and fall of acute rheumatic fever and rheumatic heart disease: a mini review
por: Liang, Yunmei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_62del9krqjv5qldstdfvjaml5d